Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

View Full Paper
Ask AI
Bookmark
Share

Authors

IKIoannis KostopoulosMDMattia D’AgostinoDŽDavid Žihala

Discussion

Loading...

Member takes

Overview

Clinical trials reveal undetectable circulating tumor cells improve prognostic value in multiple myeloma patients, indicating a distinct subtype.

Key Points

  • To investigate the clinical and biological features of multiple myeloma patients with undetectable circulating tumor cells.
  • Included 3,146 patients in clinical trials
  • Assess clinical outcomes linked to undetectable CTCs
  • Molecular alterations evaluated by exome and RNA sequencing
  • Prognostic value explored after induction therapy
  • 10% of newly diagnosed MM patients had undetectable CTCs before treatment
  • Patients with undetectable CTCs showed 80% 5-year PFS and 92% OS rates
  • Undetectable CTCs were independent prognostic factors for survival with significant HR improvements

Cite This Study

Kostopoulos et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08ahttps://doi.org/10.1182/blood-2025-366
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma2024 · 12 citations
  2. 2Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant2025
  3. 3Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.2025 · 2 citations
  4. 4Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025
  5. 5Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells2025 · 1 citations